Answers are grounded in this paper and cite their sources.
Anaphylaxis, defined as a severe and life-threatening systemic allergic reaction, is managed by several proposed treatment modalities.Intramuscular injection of epinephrine is the treatment of choice.If it is not effective, additional doses of epinephrine should be given promptly.Various second-line therapies other than epinephrine are considered.Here, the author first reports a case of nafamostat mesylate-induced refractory anaphylaxis which was successfully managed by methylene blue in a 14-year-old boy with a prior history of anaphylaxis during continuous renal replacement therapy.To elucidate the causative agent, an intradermal test was done using the anticoagulant, nafamostat mesylate, which triggered a hypersensitive reaction.Despite treatment adhering to guidelines, including two doses of intramuscular epinephrine followed by continuous infusion of epinephrine and vasopressors, and administration of glucocorticoids, histamine H1 and H2 antagonists, and multiple crystalloid boluses, severe lactic acidosis with wide pulse pressure was not resolved.When methylene blue was administered as a rescue therapy, the clinical situation began to improve.This case highlights the usefulness of methylene blue in managing refractory anaphylaxis.
No takes yet. Share an insight, caveat, or question.
You Sun Kim (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: